Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TELA Bio, Inc. TELA
$9.57
-$0.37 (-3.92%)
На 18:02, 12 мая 2023
+82.86%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
238339332.00000000
-
week52high
13.18
-
week52low
5.15
-
Revenue
41418000
-
P/E TTM
-4
-
Beta
0.97347400
-
EPS
-2.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 13 авг 2020 г. |
| Jefferies | Buy | Buy | 09 июл 2020 г. |
| JMP Securities | Market Outperform | Market Outperform | 18 июн 2020 г. |
| Canaccord Genuity | Buy | Buy | 10 июн 2020 г. |
| JMP Securities | Market Outperform | Market Outperform | 13 мая 2020 г. |
| Piper Sandler | Overweight | Overweight | 10 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Opaleye Management Inc. | A | 124813 | 1262 | 03 ноя 2022 г. |
| Opaleye Management Inc. | A | 1948000 | 19000 | 03 ноя 2022 г. |
| Opaleye Management Inc. | A | 123551 | 1000 | 11 окт 2022 г. |
| Opaleye Management Inc. | A | 1929000 | 15000 | 11 окт 2022 г. |
| Opaleye Management Inc. | A | 122551 | 304 | 23 сент 2022 г. |
| Opaleye Management Inc. | A | 1914000 | 6500 | 23 сент 2022 г. |
| Opaleye Management Inc. | A | 122247 | 1000 | 19 сент 2022 г. |
| Opaleye Management Inc. | A | 1907500 | 17000 | 19 сент 2022 г. |
| Opaleye Management Inc. | A | 121247 | 372 | 16 сент 2022 г. |
| Opaleye Management Inc. | A | 1890500 | 2000 | 16 сент 2022 г. |
Новостная лента
TELA Bio, Inc. (TELA) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 16:59
TELA Bio, Inc. (NASDAQ:TELA ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and CEO Roberto Cuca - COO and CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Phil Dantoin - Piper Sandler Kyle Rose - Canaccord Genuity Dave Turkaly - JMP Securities Zach Weiner - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 18:48
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio to Announce Third Quarter 2022 Financial Results
GlobeNewsWire
27 окт 2022 г. в 07:00
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the company will report third quarter 2022 financial results on Wednesday, November 9th, 2022. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
InvestorPlace
05 окт 2022 г. в 11:00
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.
TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Seeking Alpha
02 окт 2022 г. в 09:31
Shares of TELA Bio have fallen by 40% since public offering in 2019. Differentiation for OviTex versus competitors in terms of clinical outcomes and economics could help them transition from niche player to broad provider.